CompuGroup Medical (COP) Q3 2024 earnings summary

Executive summary

• Leadership transition brought a new CEO with deep healthcare and IT expertise, emphasizing customer needs, innovation, and operational efficiency.

• AI and cloud-based solutions, including CGM ONE and CGM STELLA, were launched to drive digital healthcare innovation and efficiency.

• Company maintains strong positions in 19 countries with a diversified healthcare customer base.

• Recurring revenues grew 6% year-over-year, now representing 75% of total revenues, offsetting declines in one-time revenues due to project delays.

• Adjusted EBITDA and margins declined year-over-year, reflecting continued R&D investment and restructuring.

Financial highlights

• Q3 2024 revenues were €283m, down 0.8%-1% year-over-year, mainly due to lower one-time revenues and project delays.

• Recurring revenues increased 6% to €213m, now 75% of total revenues.

• Adjusted EBITDA for Q3 was €55m (margin 19%), and adjusted EPS was €0.35, both down year-over-year.

• Free cash flow for nine months was €56m, down from €90m prior year, but improved sequentially in Q3.

• Net debt increased, reaching €777m due to share buybacks, acquisitions, and higher bank loan utilization.

Outlook and guidance

• 2024 organic revenue guidance revised to -2% to 0% growth; adjusted EBITDA guidance set between €202m and €250m.

• Recurring revenue share expected between 65%-70%; adjusted EPS guidance €1.55–€1.95; free cash flow expected €40m–€60m.

• Segment guidance: AIS expected to decline, HIS and PCS to grow low to mid-single digits.